shutterstock_503973673_i_wei_huang
I Wei Huang / Shutterstock.com
26 May 2022EuropeLydia Birch

Neurim, Flynn discover that time is not on their side

In the third chapter of Neurim and Flynn’s dispute with generic companies, handed down on April 23, Mr Justice Mellor refused the claimants’ application for an interim injunction against generic giant, Teva, on the basis that Teva would not be adequately compensated by damages if its melatonin product was taken off the market.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
30 April 2026   Data from Questel indicates a radical restructuring of IP professionals’ duties, as adoption and demand rates continue to rise.
Europe
30 April 2026   The company’s rivals convinced an EPO appeals board to revoke a patent that had been used in litigation against them over Comirnaty.
Europe
24 April 2026   An opinion has put pressure on the CJEU to clarify a long-running grey area that could change the game for how drug makers secure supplementary protection certificates across Europe.